Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) traded up 2.2% during trading on Wednesday . The company traded as high as $69.40 and last traded at $69.67. 3,543,302 shares traded hands during trading, a decline of 47% from the average session volume of 6,626,768 shares. The stock had previously closed at $68.20.
Analysts Set New Price Targets
A number of equities research analysts have commented on the company. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, BMO Capital Markets restated a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of "Moderate Buy" and a consensus target price of $135.00.
View Our Latest Research Report on NVO
Novo Nordisk A/S Price Performance
The firm has a market capitalization of $307.88 billion, a price-to-earnings ratio of 20.94, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock's fifty day moving average price is $67.00 and its two-hundred day moving average price is $83.76.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion during the quarter. Equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.
Institutional Investors Weigh In On Novo Nordisk A/S
A number of institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. boosted its holdings in Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after acquiring an additional 23,223 shares during the period. Bryn Mawr Capital Management LLC increased its stake in Novo Nordisk A/S by 358.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after purchasing an additional 30,420 shares during the last quarter. Clear Creek Financial Management LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $450,000. DSM Capital Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 16.7% during the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock valued at $172,678,000 after acquiring an additional 286,912 shares during the period. Finally, Patrick M Sweeney & Associates Inc. grew its holdings in Novo Nordisk A/S by 81.2% in the 4th quarter. Patrick M Sweeney & Associates Inc. now owns 11,155 shares of the company's stock worth $960,000 after buying an additional 5,000 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.
About Novo Nordisk A/S
(
Get Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
